![]() |
市場調查報告書
商品編碼
1820076
自然殺手細胞治療市場報告(按治療、應用、最終用戶和地區分類)2025-2033Natural Killer Cells Therapeutics Market Report by Therapeutics, Application, End User, and Region 2025-2033 |
2024年,全球自然殺手細胞治療市場規模達32億美元。展望未來, IMARC Group預計到2033年,該市場規模將達到86億美元,2025-2033年期間的複合年成長率(CAGR)為11.8%。癌症患病風險的上升以及老年人口的不斷成長,正在推動市場的發展。
聯合療法日益普及
將NK細胞療法與其他治療方式結合以增強療效的做法正日益受到關注。例如,Innate Pharma的抗CD22免疫毒素Lumoxiti與NK細胞聯合使用,用於破壞並靶向毛細胞白血病中表達CD22的癌細胞。此外,這種方法充分利用了兩種療法的優勢。此外,2024年5月,致力於開發用於自體免疫、癌症和傳染病的創新細胞治療平台的生物製藥公司Coeptis Therapeutics Holdings, Inc.推出了SNAP-CAR NK細胞,用於靶向多種抗原。
監管部門批准不斷增加
政府機構日益重視提高NK細胞生產的可靠性和效率,這已成為推動市場成長的重要因素。此外,政府機構也鼓勵將實驗室研究轉化為可行的臨床療法,這將在可預見的未來持續推動市場發展。例如,2024年4月,新一代NK細胞療法的領先創新者Ingenium Therapeutics獲得了美國食品藥物管理局(FDA)頒發的治療急性髓性白血病(AML)的孤兒藥資格認定。
即時監控需求不斷成長
即時監測和資料分析廣泛應用於NK細胞療法的開發,正在提高治療精準度和患者療效。此外,像Bio-Techne的Ella系統這樣的平台能夠精確監測NK細胞擴增過程中細胞激素的產生,從而確保最佳的細胞功能。即時分析還允許研究人員動態調整培養條件,這有助於提高NK細胞的品質和有效性。這對市場產生了正面的影響。
The global natural killer cells therapeutics market size reached USD 3.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 8.6 Billion by 2033, exhibiting a growth rate (CAGR) of 11.8% during 2025-2033. The rising risks of developing cancer, along with the expanding geriatric population, are propelling the market.
Increasing Popularity of Combination Therapies
Combining NK cell therapies with other treatment modalities to enhance therapeutic efficacy is gaining extensive traction. For example, Innate Pharma's Lumoxiti, an anti-CD22 immunotoxin, is adopted in conjunction with NK cells to destroy and target CD22-expressing cancer cells in hairy cell leukemia. Moreover, this approach leverages the strengths of both therapies. Besides this, in May 2024, Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company developing innovative cell therapy platforms for autoimmune, cancer, and infectious diseases, introduced SNAP-CAR NK cells to target multiple antigens.
Growing Regulatory Approval
The rising focus among government agencies on enhancing the reliability and efficiency of NK cell production is acting as a significant growth-inducing factor. Furthermore, they are encouraging the translation of laboratory research into viable clinical therapies, which will continue to fuel the market over the foreseeable future. For example, in April 2024, Ingenium Therapeutics, a leading innovator in next-generation NK cell therapies, received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).
Rising Demand for Real-Time Monitoring
The widespread integration of real-time monitoring and data analytics into NK cell therapy development is enhancing treatment precision and patient outcomes. Moreover, platforms like Bio-Techne's Ella system enable precise monitoring of cytokine production during NK cell expansion, thereby ensuring optimal cell functionality. Real-time analytics also allow researchers to adjust culture conditions dynamically, which aids in improving the quality and effectiveness of the NK cells produced. This is positively influencing the market.
Currently, NK cell directed antibodies hold the majority of the total market share
NK cell directed antibodies target natural killer cells to enhance their ability to recognize and destroy cancer cells. For example, Affimed's AFM13, a bispecific NK cell engager, targets CD30 on cancer cells and CD16A on NK cells.
Cancer currently exhibits a clear dominance in the market
The inflating need for effective cancer treatments drives the segment's growth. Recent product launches have underscored the potential of NK cell-based therapies in oncology. For instance, Fate Therapeutics' FT596 is an off-the-shelf, iPSC-derived NK cell therapy designed to target multiple cancer types, including B-cell malignancies.
Currently, research centers and institutes hold the majority of the total market share
Research centers and institutes offer high-quality reagents and technologies that streamline NK cell research, which is increasing the natural killer cells therapeutics market share. For example, Bio-Techne's Cloudz Human NK Cell Expansion Kit allows researchers to expand NK cells ex vivo efficiently.
North America exhibits a clear dominance in the market
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
Advancements in biotechnology and a strong focus on innovative cancer treatments are primarily catalyzing the market in North America. According to the IMARC, the United States cancer immunotherapy market size is projected to exhibit a growth rate (CAGR) of 10.90% during 2024-2032. Besides this, collaborations between biotech firms are strengthening the regional market.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include: